{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:04:45Z","timestamp":1793293485416,"version":"4.5.0"},"reference-count":196,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ50059"],"award-info":[{"award-number":["2023JJ50059"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cancergen.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:37:25Z","timestamp":1768088245000},"page":"27-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["M6A methylation in thyroid cancer: Functions, mechanisms, and clinical significance"],"prefix":"10.1016","volume":"302-303","author":[{"given":"Dongye","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoya","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaorong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-2168","authenticated-orcid":false,"given":"Wenkuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0001","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.32604\/or.2024.047382","article-title":"COL4A2 enhances thyroid cancer cell proliferation through the AKT pathway","volume":"32","author":"He","year":"2024","journal-title":"Oncol Res"},{"issue":"11","key":"10.1016\/j.cancergen.2026.01.005_bib0002","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.3390\/ijms26115173","article-title":"Thyroid cancer: epidemiology, classification, risk factors, diagnostic and prognostic markers, and current treatment strategies","volume":"26","author":"Forma","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.cancergen.2026.01.005_bib0003","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.3390\/jcm13206119","article-title":"Aggressive types of malignant thyroid neoplasms","volume":"13","author":"Boudina","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0004","article-title":"Unravelling the rise in thyroid cancer incidence and addressing overdiagnosis","author":"Chen","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.cancergen.2026.01.005_bib0005","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1245\/s10434-025-17498-0","article-title":"Ablative therapies in low-risk thyroid cancer","volume":"32","author":"Hu","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2213-8587(24)00276-6","article-title":"Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial","volume":"13","author":"Leboulleux","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-72002-0","article-title":"Assessing radioiodine therapy long-term outcomes in differentiated thyroid cancer using nomograms","volume":"14","author":"Alshwayyat","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0008","article-title":"Anaplastic thyroid cancer: an update","volume":"37","author":"Rao","year":"2023","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.cancergen.2026.01.005_bib0009","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1007\/s12325-020-01391-1","article-title":"Papillary thyroid cancer-aggressive variants and impact on management: a narrative review","volume":"37","author":"Coca-Pelaz","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114500","article-title":"Targeted therapy and drug resistance in thyroid cancer","volume":"238","author":"Zhang","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0011","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1186\/s12935-021-02405-w","article-title":"Epigenetic modification and BRAF gene mutation in thyroid carcinoma","volume":"21","author":"Huang","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"10","key":"10.1016\/j.cancergen.2026.01.005_bib0012","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1039\/C6CS00599C","article-title":"Epigenetic modification of nucleic acids: from basic studies to medical applications","volume":"46","author":"Chen","year":"2017","journal-title":"Chem Soc Rev"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0013","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.molcel.2017.10.030","article-title":"Protein-based inheritance: epigenetics beyond the chromosome","volume":"69","author":"Harvey","year":"2018","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0014","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","article-title":"Functions of N6-methyladenosine and its role in cancer","volume":"18","author":"He","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0016","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13046-020-01706-8","article-title":"m6A modification in RNA: biogenesis, functions and roles in gliomas","volume":"39","author":"Zhang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.cancergen.2026.01.005_bib0017","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1073\/pnas.71.10.3971","article-title":"Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells","volume":"71","author":"Desrosiers","year":"1974","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0018","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12943-023-01810-1","article-title":"Epigenetic modification of m6A regulator proteins in cancer","volume":"22","author":"Wang","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0019","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-020-01204-7","article-title":"The potential role of RNA N6-methyladenosine in cancer progression","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108613","article-title":"The role of m6A RNA methylation in cancer","volume":"112","author":"Sun","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"10.1016\/j.cancergen.2026.01.005_bib0021","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1021\/bi00627a023","article-title":"Nucleotide sequences at the N6-methyladenosine sites of HeLa cell messenger ribonucleic acid","volume":"16","author":"Wei","year":"1977","journal-title":"Biochemistry"},{"issue":"7","key":"10.1016\/j.cancergen.2026.01.005_bib0022","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.cell.2012.05.003","article-title":"Comprehensive analysis of mRNA methylation reveals enrichment in 3\u2019 UTRs and near stop codons","volume":"149","author":"Meyer","year":"2012","journal-title":"Cell"},{"issue":"7397","key":"10.1016\/j.cancergen.2026.01.005_bib0023","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature11112","article-title":"Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq","volume":"485","author":"Dominissini","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cancergen.2026.01.005_bib0024","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/gb-2012-13-10-175","article-title":"The birth of the epitranscriptome: deciphering the function of RNA modifications","volume":"13","author":"Saletore","year":"2012","journal-title":"Genome Biol"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-67417-w","article-title":"Comprehensive discovery of m6A sites in the human transcriptome at single-molecule resolution","author":"Kang","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0026","doi-asserted-by":"crossref","first-page":"qzae039","DOI":"10.1093\/gpbjnl\/qzae039","article-title":"Scm6A: a fast and low-cost method for quantifying m6A modifications at the single-cell level","volume":"22","author":"Li","year":"2024","journal-title":"Genom Proteom Bioinform"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0027","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/anie.201710209","article-title":"Engineering of a DNA polymerase for direct m6 A sequencing","volume":"57","author":"Aschenbrenner","year":"2018","journal-title":"Angew Chem Int Engl"},{"issue":"7","key":"10.1016\/j.cancergen.2026.01.005_bib0028","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.32604\/or.2025.062747","article-title":"N6-Methyladenosine promotes the transcription of c-src kinase via IRF1 to facilitate the proliferation of liver cancer","volume":"33","author":"Peng","year":"2025","journal-title":"Oncol Res"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13578-021-00583-8","article-title":"The crucial roles of N6-methyladenosine (m6A) modification in the carcinogenesis and progression of colorectal cancer","volume":"11","author":"Fang","year":"2021","journal-title":"Cell Biosci"},{"issue":"13","key":"10.1016\/j.cancergen.2026.01.005_bib0030","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.3390\/cancers15133307","article-title":"The regulation of m6A modification in glioblastoma: functional mechanisms and therapeutic approaches","volume":"15","author":"Deacon","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101063","article-title":"Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer","volume":"73","author":"Ou","year":"2024","journal-title":"Drug Resist Updat"},{"issue":"8","key":"10.1016\/j.cancergen.2026.01.005_bib0032","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.32604\/or.2025.061301","article-title":"OTUD7B Stabilization by METTL14-mediated m6A methylation drives HIF-1\u03b1 expression in esophageal Squamous cell carcinoma","volume":"33","author":"Ren","year":"2025","journal-title":"Oncol Res"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0033","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41416-023-02246-6","article-title":"The critical roles of m6A RNA methylation in lung cancer: from mechanism to prognosis and therapy","volume":"129","author":"Diao","year":"2023","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0034","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-022-00298-7","article-title":"Role of m6A writers, erasers and readers in cancer","volume":"11","author":"Fang","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev-cellbio-100616-060758","article-title":"Rethinking m6A readers, writers, and erasers","volume":"33","author":"Meyer","year":"2017","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.cancergen.2026.01.005_bib0036","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.3390\/ijms26072833","article-title":"The role of M6A LncRNA modification in papillary thyroid cancer","volume":"26","author":"Klausner","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0037","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41417-023-00628-9","article-title":"RNA N6-methyladenosine (m6A) modification in HNSCC: molecular mechanism and therapeutic potential","volume":"30","author":"Sun","year":"2023","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0038","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/jcmm.17091","article-title":"ALKBH5-mediated m6A modification of lncRNA KCNQ1OT1 triggers the development of LSCC via upregulation of HOXA9","volume":"26","author":"Li","year":"2022","journal-title":"J Cell Mol Med"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0039","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41417-023-00702-2","article-title":"m6A reader IGF2BP2 promotes lymphatic metastasis by stabilizing DPP4 in papillary thyroid carcinoma","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"10.1016\/j.cancergen.2026.01.005_bib0040","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/tox.24139","article-title":"N6-Methyladenosine reader HNRNPC-mediated downregulation of circITCH prevents miR-224-3p sequestering and contributes to tumorigenesis in nasopharyngeal carcinoma","volume":"39","author":"Zhou","year":"2024","journal-title":"Env Toxicol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0041","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","article-title":"Roles of METTL3 in cancer: mechanisms and therapeutic targeting","volume":"13","author":"Zeng","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0042","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nchembio.1432","article-title":"A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation","volume":"10","author":"Liu","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0043","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/cr.2014.3","article-title":"Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase","volume":"24","author":"Ping","year":"2014","journal-title":"Cell Res"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217698","article-title":"RNA methyltransferase METTL16: from molecular mechanisms to therapeutic prospects in cancers","volume":"624","author":"Shi","year":"2025","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.cancergen.2026.01.005_bib0045","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/biom14101319","article-title":"N6-Methyladenosine methyltransferase component KIAA1429 is a potential target of cancer therapy","volume":"14","author":"Huang","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1375942","article-title":"Exploring the role of m 6 A writer RBM15 in cancer: a systematic review","volume":"14","author":"Cao","year":"2024","journal-title":"Front Oncol"},{"issue":"5\u20136","key":"10.1016\/j.cancergen.2026.01.005_bib0047","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1101\/gad.309146.117","article-title":"Zc3h13\/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15\/spenito to the m6A machinery component Wtap\/Fl(2)d","volume":"32","author":"Knuckles","year":"2018","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0048","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13578-024-01286-6","article-title":"Insights into the m6A demethylases FTO and ALKBH5 : structural, biological function, and inhibitor development","volume":"14","author":"Gao","year":"2024","journal-title":"Cell Biosci"},{"issue":"Pt 3","key":"10.1016\/j.cancergen.2026.01.005_bib0049","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2022.05.009","article-title":"The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer","volume":"86","author":"Ramesh-Kumar","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.tig.2021.11.005","article-title":"The multifaceted effects of YTHDC1-mediated nuclear m6A recognition","volume":"38","author":"Widagdo","year":"2022","journal-title":"Trends Genet"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0051","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12967-024-05293-6","article-title":"The biological function of the N6-methyladenosine reader YTHDC2 and its role in diseases","volume":"22","author":"Wu","year":"2024","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0052","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40364-023-00452-1","article-title":"The function and clinical implication of YTHDF1 in the human system development and cancer","volume":"11","author":"Ren","year":"2023","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.cancergen.2026.01.005_bib0053","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.it.2025.04.003","article-title":"YTHDF2: a key RNA reader and antitumor target","volume":"46","author":"Xiao","year":"2025","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0054","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/cr.2017.15","article-title":"YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA","volume":"27","author":"Shi","year":"2017","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40364-022-00366-4","article-title":"An analysis of the role of HnRNP C dysregulation in cancers","volume":"10","author":"Mo","year":"2022","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.cancergen.2026.01.005_bib0056","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2015.08.011","article-title":"HNRNPA2B1 Is a mediator of m(6)A-dependent nuclear RNA processing events","volume":"162","author":"Alarc\u00f3n","year":"2015","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.cancergen.2026.01.005_bib0057","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1038\/s41418-023-01217-x","article-title":"METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer","volume":"30","author":"Ning","year":"2023","journal-title":"Cell Death Differ"},{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0058","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.7150\/ijbs.84797","article-title":"METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8","volume":"20","author":"Kang","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0059","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1210\/clinem\/dgab480","article-title":"METTL3-Induced miR-222-3p upregulation inhibits STK4 and promotes the malignant behaviors of thyroid carcinoma cells","volume":"107","author":"Lin","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2024.101987","article-title":"METTL14-mediated m6A modification upregulated SOCS3 expression alleviates thyroid cancer progression by regulating the JAK2\/STAT3 pathway","volume":"78","author":"Zhou","year":"2024","journal-title":"Mol Cell Probes"},{"issue":"Pt 4","key":"10.1016\/j.cancergen.2026.01.005_bib0061","article-title":"Investigating the mechanism of METTL16-dependent m6A modification regulating the SAMD11 protein signaling pathway to inhibit thyroid cancer phenotypes","volume":"280","author":"Liu","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0062","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00018-024-05146-x","article-title":"METTL16 inhibits papillary thyroid cancer tumorigenicity through m(6)A\/YTHDC2\/SCD1-regulated lipid metabolism","volume":"81","author":"Li","year":"2024","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"10.1016\/j.cancergen.2026.01.005_bib0063","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jfma.2022.12.019","article-title":"Overexpressed ZC3H13 suppresses papillary thyroid carcinoma growth through m6A modification-mediated IQGAP1 degradation","volume":"122","author":"Xie","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"10.1016\/j.cancergen.2026.01.005_bib0064","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/cas.15772","article-title":"ALKBH5-induced circular RNA NRIP1 promotes glycolysis in thyroid cancer cells by targeting PKM2","volume":"114","author":"Ji","year":"2023","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0065","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11010-022-04541-x","article-title":"ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2\/HO-1 axis","volume":"478","author":"Li","year":"2023","journal-title":"Mol Cell Biochem"},{"issue":"10","key":"10.1016\/j.cancergen.2026.01.005_bib0066","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41419-024-07097-4","article-title":"FTO\/IGF2BP2-mediated N6 methyladenosine modification in invasion and metastasis of thyroid carcinoma via CDH12","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0067","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13046-022-02254-z","article-title":"FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner","volume":"41","author":"Huang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.857765","article-title":"FTO prevents thyroid cancer progression by SLC7A11 m6A methylation in a ferroptosis-dependent manner","volume":"13","author":"Ji","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0069","article-title":"IGF2BP2 knockdown suppresses thyroid cancer progression by reducing the expression of long non-coding RNA HAGLR","volume":"225","author":"Dong","year":"2021","journal-title":"Pathol Res Pr."},{"key":"10.1016\/j.cancergen.2026.01.005_bib0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2021.12.005","article-title":"IGF2BP2-dependent activation of ERBB2 signaling contributes to acquired resistance to tyrosine kinase inhibitor in differentiation therapy of radioiodine-refractory papillary thyroid cancer","volume":"527","author":"Sa","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0071","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.freeradbiomed.2025.02.025","article-title":"N6-methyladenosine-mediated EIF3H promotes anaplastic thyroid cancer progression and ferroptosis resistance by stabilizing \u03b2-catenin","volume":"231","author":"Zhang","year":"2025","journal-title":"Free Radic Biol Med"},{"issue":"32","key":"10.1016\/j.cancergen.2026.01.005_bib0072","article-title":"SETMAR facilitates the differentiation of thyroid cancer by regulating SMARCA2-mediated chromatin remodeling","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0073","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41419-022-04817-6","article-title":"METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0074","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12010-023-04540-8","article-title":"YTHDC2 Retards cell proliferation and triggers apoptosis in papillary thyroid cancer by regulating CYLD-mediated inactivation of Akt signaling","volume":"196","author":"Zhou","year":"2024","journal-title":"Appl Biochem Biotechnol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13062-024-00566-y","article-title":"YTHDF2 promotes anaplastic thyroid cancer progression by activating the DDIT4\/AKT\/mTOR signaling pathway","volume":"19","author":"Dai","year":"2024","journal-title":"Biol Direct"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139150","article-title":"YTHDF3-induced degradation of P4HA2 mRNA inhibits glycolysis in papillary thyroid cancer through Hippo signaling pathway","volume":"291","author":"Ding","year":"2025","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0077","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12967-025-06130-0","article-title":"Correction to: HNRNPC modulates PKM alternative splicing via m6A methylation, upregulating PKM2 expression to promote aerobic glycolysis in papillary thyroid carcinoma and drive malignant progression","volume":"23","author":"Rong","year":"2025","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0078","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.molcel.2016.03.021","article-title":"The m(6)A methyltransferase METTL3 promotes translation in Human cancer cells","volume":"62","author":"Lin","year":"2016","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0079","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","article-title":"Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases","volume":"63","author":"Wang","year":"2016","journal-title":"Mol Cell"},{"issue":"10","key":"10.1016\/j.cancergen.2026.01.005_bib0080","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41419-022-05268-9","article-title":"The RNA m6A writer WTAP in diseases: structure, roles, and mechanisms","volume":"13","author":"Huang","year":"2022","journal-title":"Cell Death Dis"},{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0081","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/procel\/pwad009","article-title":"METTL14 is a chromatin regulator independent of its RNA N6-methyladenosine methyltransferase activity","volume":"14","author":"Dou","year":"2023","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0082","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13062-024-00499-6","article-title":"Epigenetic mechanism of RBM15 in affecting cisplatin resistance in laryngeal carcinoma cells by regulating ferroptosis","volume":"19","author":"Liang","year":"2024","journal-title":"Biol Direct"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0083","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13046-021-01871-4","article-title":"RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent","volume":"40","author":"Wang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.cancergen.2026.01.005_bib0084","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/jop.13568","article-title":"The novel m6A writer methyltransferase 5 is a promising prognostic biomarker and associated with immune cell infiltration in oral squamous cell carcinoma","volume":"53","author":"Muthumanickam","year":"2024","journal-title":"J Oral Pathol Med"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/jop.13531","article-title":"Inhibin A contributes to the tumorigenesis of oral squamous cell carcinoma by KIAA1429-mediated m6A modification","volume":"53","author":"Chen","year":"2024","journal-title":"J Oral Pathol Med"},{"issue":"7","key":"10.1016\/j.cancergen.2026.01.005_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104873","article-title":"m6A-enriched lncRNA LINC00839 promotes tumor progression by enhancing TAF15-mediated transcription of amine oxidase AOC1 in nasopharyngeal carcinoma","volume":"299","author":"Zheng","year":"2023","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.cancergen.2026.01.005_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104677","article-title":"VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner","volume":"299","author":"Zheng","year":"2023","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.cancergen.2026.01.005_bib0088","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.17305\/bb.2024.10358","article-title":"VIRMA promotes the progression of head and neck squamous cell carcinoma by regulating UBR5 mRNA and m6A levels","volume":"24","author":"Zhu","year":"2024","journal-title":"Biomol Biomed"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2023.102187","article-title":"ZC3H13 reduced DUOX1-mediated ferroptosis in laryngeal squamous cell carcinoma cells through m6A-dependent modification","volume":"84","author":"Huang","year":"2023","journal-title":"Tissue Cell"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s40001-023-01382-2","article-title":"The emerging roles of N6-methyladenosine RNA modifications in thyroid cancer","volume":"28","author":"Xu","year":"2023","journal-title":"Eur J Med Res"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0091","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-022-01522-y","article-title":"Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification","volume":"21","author":"Hu","year":"2022","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.cancergen.2026.01.005_bib0092","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nchembio.687","article-title":"N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO","volume":"7","author":"Jia","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0093","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molcel.2012.10.015","article-title":"ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility","volume":"49","author":"Zheng","year":"2013","journal-title":"Mol Cell"},{"issue":"7","key":"10.1016\/j.cancergen.2026.01.005_bib0094","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.trecan.2022.02.010","article-title":"FTO in cancer: functions, molecular mechanisms, and therapeutic implications","volume":"8","author":"Li","year":"2022","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12902-023-01510-3","article-title":"m6A modification patterns are associated with copy number burden and tumor immune landscape in thyroid cancer","volume":"23","author":"Cai","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0096","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/s41598-024-84352-w","article-title":"ALKBH5, an m6A demethylase, attenuates tumor growth and inhibits metastasis in papillary thyroid carcinoma","volume":"15","author":"Zhuang","year":"2025","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0097","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3892\/ijmm.2025.5605","article-title":"m6A modification of non-coding RNA: mechanisms, functions and potential values in human diseases (Review)","volume":"56","author":"Yi","year":"2025","journal-title":"Int J Mol Med"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0098","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.molcel.2016.01.012","article-title":"Nuclear m(6)A reader YTHDC1 regulates mRNA splicing","volume":"61","author":"Xiao","year":"2016","journal-title":"Mol Cell"},{"issue":"7540","key":"10.1016\/j.cancergen.2026.01.005_bib0099","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nature14234","article-title":"N.(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions","volume":"518","author":"Liu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0100","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijbiomac.2022.09.104","article-title":"Emerging roles of hnRNP A2B1 in cancer and inflammation","volume":"221","author":"Xu","year":"2022","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"10.1016\/j.cancergen.2026.01.005_bib0101","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","article-title":"N(6)-methyladenosine modulates messenger RNA translation efficiency","volume":"161","author":"Wang","year":"2015","journal-title":"Cell"},{"issue":"7481","key":"10.1016\/j.cancergen.2026.01.005_bib0102","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature12730","article-title":"N6-methyladenosine-dependent regulation of messenger RNA stability","volume":"505","author":"Wang","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0103","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/cr.2017.99","article-title":"Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis","volume":"27","author":"Hsu","year":"2017","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0104","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","article-title":"Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation","volume":"20","author":"Huang","year":"2018","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s12935-021-02090-9","article-title":"The functions and prognostic values of m6A RNA methylation regulators in thyroid carcinoma","volume":"21","author":"Yu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106933","article-title":"Targeting hnRNPC suppresses thyroid follicular epithelial cell apoptosis and necroptosis through m(6)A-modified ATF4 in autoimmune thyroid disease","volume":"196","author":"Mo","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0107","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.666393","article-title":"METTL3 Is involved in the development of Graves\u2019 Disease by inducing SOCS mRNA m6A modification","volume":"12","author":"Song","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0108","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/dna.2024.0197","article-title":"METTL3-Induced m6A modification enhances Hsa_Circ_0136959 expression to impair the tumor characteristics of papillary thyroid carcinoma via accelerating ferroptosis","volume":"44","author":"Luo","year":"2025","journal-title":"DNA Cell Biol"},{"issue":"5","key":"10.1016\/j.cancergen.2026.01.005_bib0109","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.ymthe.2021.01.019","article-title":"METTL3 restrains papillary thyroid cancer progression via m6A\/c-rel\/IL-8-mediated neutrophil infiltration","volume":"29","author":"He","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2025.102902","article-title":"METTL3-mediated m6A modification of MT1G inhibits papillary thyroid carcinoma cell growth and metastasis via wnt\/\u03b2-catenin pathway","volume":"95","author":"Liu","year":"2025","journal-title":"Tissue Cell"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0111","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1615\/CritRevImmunol.2023050267","article-title":"m6A Writer METTL3-mediated lncRNA LINC01125 prevents the malignancy of papillary thyroid cancer","volume":"43","author":"He","year":"2023","journal-title":"Crit Rev Immunol"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0112","doi-asserted-by":"crossref","first-page":"623","DOI":"10.17219\/acem\/188367","article-title":"LncRNA LINC00969 modified by METTL3 attenuates papillary thyroid cancer progression in an m6A-dependent manner","volume":"34","author":"Huang","year":"2025","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0113","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12935-024-03240-5","article-title":"The m6A methyltransferase METTL3 drives thyroid cancer progression and lymph node metastasis by targeting LINC00894","volume":"24","author":"Zhou","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"6","key":"10.1016\/j.cancergen.2026.01.005_bib0114","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/0118715303290063240530053252","article-title":"METTL3-mediated m6A modification of hsa_circ_0131922 attenuates the progression of papillary thyroid cancer by regulating the p53 pathway","volume":"25","author":"Li","year":"2025","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0115","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s12672-025-03482-3","article-title":"N(6)-methyladenosine modification of ADGRA3 by ZC3H13 suppresses papillary thyroid cancer cell malignancy by inactivating the PI3K\/akt\/mTOR signaling pathway","volume":"16","author":"Cai","year":"2025","journal-title":"Discov Oncol"},{"issue":"12","key":"10.1016\/j.cancergen.2026.01.005_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32913","article-title":"hsa_circ_0101050 regulated by ZC3H13 enhances tumorigenesis in papillary thyroid cancer via m(6)A modification","volume":"10","author":"Lv","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0117","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10565-025-10073-z","article-title":"FTO-mediated the destabilization of RASGRF1 mRNA impedes thyroid cancer progression and suppresses macrophage M2 polarization","volume":"41","author":"Li","year":"2025","journal-title":"Cell Biol Toxicol"},{"issue":"5","key":"10.1016\/j.cancergen.2026.01.005_bib0118","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s40618-023-02241-x","article-title":"CircNRCAM up-regulates NRCAM to promote papillary thyroid carcinoma progression","volume":"47","author":"Wang","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0119","doi-asserted-by":"crossref","DOI":"10.1177\/09603271231180856","article-title":"LINC00641 impeded the malignant biological behaviors of papillary thyroid carcinoma cells via interacting with IGF2BP1 to reduce GLI1 mRNA stability","volume":"42","author":"Meng","year":"2023","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2020.09.023","article-title":"Oncogenic role of long noncoding RNAMALAT1 in thyroid cancer progression through regulation of the miR-204\/IGF2BP2\/m6A-MYC signaling","volume":"23","author":"Ye","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0121","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10616-025-00755-1","article-title":"Mechanism of the N6-methyladenosine reader heterogeneous nuclear ribonucleoprotein C facilitating immune escape in thyroid cancer by stabilizing programmed death ligand 1","volume":"77","author":"Li","year":"2025","journal-title":"Cytotechnology"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0122","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0123","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0124","doi-asserted-by":"crossref","DOI":"10.1177\/0036850421997273","article-title":"A review of the mechanism of DDIT4 serve as a mitochondrial related protein in tumor regulation","volume":"104","author":"Ding","year":"2021","journal-title":"Sci Prog"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.142797","article-title":"STEAP proteins: roles in disease biology and potential for therapeutic intervention","volume":"309","author":"Cai","year":"2025","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"10.1016\/j.cancergen.2026.01.005_bib0126","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/1541-7786.MCR-11-0281","article-title":"STEAP proteins: from structure to applications in cancer therapy","volume":"10","author":"Gomes","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"6487","key":"10.1016\/j.cancergen.2026.01.005_bib0127","doi-asserted-by":"crossref","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113702","article-title":"Emerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer","volume":"144","author":"Li","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"10.1016\/j.cancergen.2026.01.005_bib0130","first-page":"1579","article-title":"Metabolic reprogramming and its clinical application in thyroid cancer","volume":"18","author":"Wen","year":"2019","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0131","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201606","article-title":"Lipid metabolism and cancer","volume":"218","author":"Bian","year":"2021","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0132","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","article-title":"Lipid metabolism reprogramming and its potential targets in cancer","volume":"38","author":"Cheng","year":"2018","journal-title":"Cancer Commun (L)"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0133","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41419-025-07340-6","article-title":"piR-26441 inhibits mitochondrial oxidative phosphorylation and tumorigenesis in ovarian cancer through m6A modification by interacting with YTHDC1","volume":"16","author":"Yuan","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0134","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217156","article-title":"the sweet appetite of the tumor microenvironment","volume":"600","author":"Kooshan","year":"2024","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1186\/s12967-023-04617-2","article-title":"The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer","volume":"21","author":"Duan","year":"2023","journal-title":"J Transl Med"},{"issue":"13","key":"10.1016\/j.cancergen.2026.01.005_bib0136","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.3390\/ijms25137129","article-title":"The role of lipid metabolism disorders in the development of thyroid cancer","volume":"25","author":"Lukasiewicz","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0137","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70357","article-title":"Programmed cell death in cancer","volume":"6","author":"Wei","year":"2025","journal-title":"MedComm"},{"issue":"7301","key":"10.1016\/j.cancergen.2026.01.005_bib0138","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1136\/bmj.322.7301.1525","article-title":"The role of apoptosis in autoimmune thyroid disorders and thyroid cancer","volume":"322","author":"Lin","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116971","article-title":"Ferroptosis in thyroid cancer: potential mechanisms, effective therapeutic targets and predictive biomarker","volume":"177","author":"Chen","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","article-title":"Ferroptosis, a new form of cell death: opportunities and challenges in cancer","volume":"12","author":"Mou","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0141","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","article-title":"Apoptosis in cancer biology and therapy","volume":"20","author":"Moyer","year":"2025","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0142","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4103\/1008-682X.126400","article-title":"Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer","volume":"16","author":"Albany","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0143","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217842","article-title":"The role of 7-dehydrocholesterol in inducing ER stress and apoptosis of head and neck squamous cell carcinoma","volume":"628","author":"Lee","year":"2025","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.cancergen.2026.01.005_bib0144","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.humimm.2015.09.037","article-title":"SOCS3 and its role in associated diseases","volume":"76","author":"Yin","year":"2015","journal-title":"Hum Immunol"},{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0145","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/0008-5472.CAN-13-1606","article-title":"Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3","volume":"74","author":"Kneitz","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0146","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/08923973.2018.1455208","article-title":"MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3\/JAK-STAT signaling pathway","volume":"40","author":"Xiao","year":"2018","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0147","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","article-title":"Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.cancergen.2026.01.005_bib0148","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0149","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-022-30217-7","article-title":"N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer","volume":"13","author":"Zou","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.cancergen.2026.01.005_bib0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","article-title":"Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy","volume":"12","author":"Koppula","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0151","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216619","article-title":"AMPK\u03b11-mediated ZDHHC8 phosphorylation promotes the palmitoylation of SLC7A11 to facilitate ferroptosis resistance in glioblastoma","volume":"584","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0152","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41418-023-01239-5","article-title":"TRIM3 facilitates ferroptosis in non-small cell lung cancer through promoting SLC7A11\/xCT K11-linked ubiquitination and degradation","volume":"31","author":"Wang","year":"2024","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0153","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jare.2024.04.009","article-title":"Tanshinone IIA destabilizes SLC7A11 by regulating PIAS4-mediated SUMOylation of SLC7A11 through KDM1A, and promotes ferroptosis in breast cancer","volume":"69","author":"Luo","year":"2025","journal-title":"J Adv Res"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0154","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13046-024-03032-9","article-title":"Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11\/GPX4 expression","volume":"43","author":"Qiao","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-024-00239-2","article-title":"Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer","volume":"6","author":"Gu","year":"2025","journal-title":"Mol Biomed"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0156","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0157","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0158","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7150\/thno.17322","article-title":"Obatoclax and LY3009120 efficiently overcome vemurafenib resistance in differentiated thyroid cancer","volume":"7","author":"Wei","year":"2017","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.cancergen.2026.01.005_bib0159","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.7150\/thno.104713","article-title":"NSUN2-mediated m5C modification drives alternative splicing reprogramming and promotes multidrug resistance in anaplastic thyroid cancer through the NSUN2\/SRSF6\/UAP1 signaling axis","volume":"15","author":"Hou","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-023-00386-2","article-title":"Emerging roles of m6A RNA modification in cancer therapeutic resistance","volume":"12","author":"Liu","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0161","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0162","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0163","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.semcancer.2019.01.004","article-title":"Signal transduction pathways and resistance to targeted therapies in glioma","volume":"58","author":"Tomiyama","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0164","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/hmg\/ddl046","article-title":"Non-coding RNA","author":"Mattick","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2017.99","article-title":"Non-coding RNA networks in cancer","volume":"18","author":"Anastasiadou","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.cancergen.2026.01.005_bib0166","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The role of non-coding RNAs in oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0167","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.32604\/or.2025.062810","article-title":"Association among noncoding-RNAs, APRO Family proteins, and gut microbiota in the development of breast cancer","volume":"33","author":"Fukumoto","year":"2025","journal-title":"Oncol Res"},{"issue":"3","key":"10.1016\/j.cancergen.2026.01.005_bib0168","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","article-title":"m6A Modification in coding and non-coding RNAs: roles and therapeutic implications in cancer","volume":"37","author":"Huang","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0169","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.cancergen.2026.01.005_bib0170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.cancergen.2026.01.005_bib0171","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.32604\/or.2024.049235","article-title":"MicroRNAs in thyroid cancer with focus on medullary thyroid carcinoma: potential therapeutic targets and diagnostic\/prognostic markers and web based tools","volume":"32","author":"Shakiba","year":"2024","journal-title":"Oncol Res"},{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0172","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.tibs.2016.07.003","article-title":"Linking long noncoding RNA localization and function","volume":"41","author":"Chen","year":"2016","journal-title":"Trends Biochem Sci"},{"issue":"15","key":"10.1016\/j.cancergen.2026.01.005_bib0173","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","article-title":"Long noncoding RNA and cancer: a new paradigm","volume":"77","author":"Bhan","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0174","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","article-title":"Circular RNA: metabolism, functions and interactions with proteins","volume":"19","author":"Zhou","year":"2020","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.cancergen.2026.01.005_bib0175","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41568-024-00721-7","article-title":"Circular RNA in cancer","volume":"24","author":"Conn","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0176","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217069","article-title":"CircPCNXL2 promotes papillary thyroid carcinoma progression by regulating fatty acid metabolism induced by anabolic enzyme ACC1","volume":"598","author":"Chu","year":"2024","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.cancergen.2026.01.005_bib0177","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","article-title":"The roles and implications of RNA m6A modification in cancer","volume":"20","author":"Deng","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0178","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12935-020-01283-y","article-title":"Identification and validation of m(6)A RNA methylation regulators with clinical prognostic value in papillary thyroid cancer","volume":"20","author":"Wang","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0179","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.995645","article-title":"Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy","volume":"13","author":"Xia","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-023-00139-x","article-title":"RNA modification: mechanisms and therapeutic targets","volume":"4","author":"Qiu","year":"2023","journal-title":"Mol Biomed"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0181","doi-asserted-by":"crossref","first-page":"bbaf361","DOI":"10.1093\/bib\/bbaf361","article-title":"Research on RNA modification in disease diagnosis and prognostic biomarkers: current status and challenges","volume":"26","author":"Shi","year":"2025","journal-title":"Br. Bioinform"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0182","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.683254","article-title":"The biological function, mechanism, and clinical significance of m6A RNA modifications in head and neck carcinoma: a systematic review","volume":"9","author":"Jing","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0183","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/s12885-023-11361-9","article-title":"YTHDF3as a prognostic predictive biomarker of thyroid cancer and its correlation with immune infiltration","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.cancergen.2026.01.005_bib0184","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2020.102547","article-title":"m(6)A RNA methylation regulators have prognostic value in papillary thyroid carcinoma","volume":"41","author":"Hou","year":"2020","journal-title":"Am J Otolaryngol"},{"issue":"17","key":"10.1016\/j.cancergen.2026.01.005_bib0185","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.7150\/jca.41193","article-title":"Prognostic values of m6A RNA methylation regulators in differentiated Thyroid Carcinoma","volume":"11","author":"Xu","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0186","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/IJGM.S449827","article-title":"Correlations of m(6)A methylation-related lncRNAs with the prognosis of papillary thyroid carcinoma","volume":"17","author":"Li","year":"2024","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0187","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112050","article-title":"Identification of m6A-related lncRNAs LINC02471 and DOCK9-DT as potential biomarkers for thyroid cancer","volume":"133","author":"Chen","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"Pt B","key":"10.1016\/j.cancergen.2026.01.005_bib0188","article-title":"Analysis of the prognostic significance and potential mechanisms of lncRNAs associated with m6A methylation in papillary thyroid carcinoma","volume":"101","author":"Huang","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10.1016\/j.cancergen.2026.01.005_bib0189","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1016\/j.ymthe.2024.10.025","article-title":"N6-Methyladenosine modification activates the serine synthesis pathway to mediate therapeutic resistance in liver cancer","volume":"32","author":"Chan","year":"2024","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.cancergen.2026.01.005_bib0190","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1158\/2159-8290.CD-23-1212","article-title":"The N6-methyladenosine epitranscriptomic landscape of lung adenocarcinoma","volume":"14","author":"Wang","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0191","first-page":"0472","article-title":"POP1 Facilitates proliferation in triple-negative breast cancer via m6A-dependent degradation of CDKN1A mRNA","volume":"7","author":"Zhang","year":"2024","journal-title":"Res. (Wash D C)"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0192","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117366","article-title":"METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3\/AKT pathway and synergizes with PARP inhibitor","volume":"179","author":"Chen","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cancergen.2026.01.005_bib0193","article-title":"The m6A methyltransferase METTL14 promotes oncogenic Kras induced juvenile myelomonocytic leukemia through dysregulating autophagy","volume":"16","author":"Zhang","year":"2025","journal-title":"Cell Death Differ"},{"issue":"19","key":"10.1016\/j.cancergen.2026.01.005_bib0194","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911516","article-title":"Role of m6A RNA methylation in thyroid cancer cell lines","volume":"23","author":"Allegri","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.cancergen.2026.01.005_bib0195","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051268","article-title":"Targeting IGF2BP2 promotes differentiation of radioiodine refractory papillary thyroid cancer via destabilizing RUNX2 mRNA","volume":"14","author":"Sa","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cancergen.2026.01.005_bib0196","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1080\/07853890.2023.2192049","article-title":"Identification of m6A-associated LncRNAs as predict factors for the immune infiltration and prognosis of thyroid cancer","volume":"55","author":"Su","year":"2023","journal-title":"Ann Med"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221077622600013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221077622600013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:45:08Z","timestamp":1773449108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221077622600013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":196,"alternative-id":["S221077622600013X"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2026.01.005","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M6A methylation in thyroid cancer: Functions, mechanisms, and clinical significance","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}